Clinical Trials Logo

Intermittent Fasting clinical trials

View clinical trials related to Intermittent Fasting.

Filter by:

NCT ID: NCT04355910 Recruiting - Obesity Clinical Trials

Intermittent Fasting in Nonalcoholic Fatty Liver Disease

Start date: January 1, 2018
Phase: N/A
Study type: Interventional

Although preliminary evidence suggests that intermittent fasting mimic-diet (IFD) exerts stronger effects on body weight and metabolic parameters, which may link obesity, non-alcoholic fatty liver disease (NAFLD) and major chronic diseases, compared with continuous calorie restriction (CCR), there is a lack of well-powered intervention studies. This randomized controlled trial will test whether IFD, operationalized as the "5:2 diet," has stronger effects on anthropometric and body composition characteristics, and circulating metabolic biomarkers than CCR and a control regimen in adults with NAFLD.

NCT ID: NCT04193995 Recruiting - Weight Loss Clinical Trials

Intermittent Fasting as a Means to Lose Fluid Overload and Weight in Complicated Obesity

Start date: April 1, 2019
Phase: N/A
Study type: Interventional

To examine the feasibility of intermittent fasting (36h, twice a week, unlimited salt and calorie-free fluid consumption), over three months, on body weight and composition in complicated obesity in whom age and medical complexity exclude the possibility of bariatric surgery.

NCT ID: NCT03805776 Recruiting - Anemia Clinical Trials

Intermittent Fasting in Dyslipidemia

Start date: February 20, 2019
Phase: N/A
Study type: Interventional

World Health Organization report notifies of the escalating global burden of cardiovascular diseases (CVD), projecting that it will become the major worldwide cause of death and disability by 2020. The South Asian countries have the highest rates of CVD globally. It is widely acknowledged that South Asians have 40-60% higher risk of CVD linked to mortality, compared with other populations. Multiple human population studies have established the concentration of high density lipoprotein (HDL) cholesterol as an independent, inverse predictor of the risk of having a cardiovascular event. Furthermore, HDLs have several well-documented functions with the potential to protect against cardiovascular disease. This study trial is designed to find out the role of intermittent fasting to improve the dyslipidemia and particularly increase the levels of HDL in general population. Investigators expect that the intermittent fasting will significantly enhance the level of HDL and reduce cardiovascular events in general population.

NCT ID: NCT03789409 Recruiting - Ischemic Stroke Clinical Trials

Intermittent Fasting Following Acute Ischemic Stroke

Start date: March 4, 2019
Phase: N/A
Study type: Interventional

Despite numerous kinds of evidence on functional health and CNS protection of intermittent fasting after injuries were found in many brain-, and spinal cord-damaged animal models, there has yet to be any clinical study of intermittent fasting after acute ischemic cerebral infarction. The aim of this study is to evaluate the neurological, functional and clinical efficacy of intermittent fasting in patients after acute ischemic stroke.